Effect of the gene dosage of CYP2C19 on diazepam metabolism in Chinese subjects

Clinical Pharmacology and Therapeutics

Volumn 66, Issue 6, 1999, Pages 642-646

  Qin, Xu Ping ^b   Xie, Hong Guang ^c   Wang, Wei ^e   He, Nan ^e   Huang, Song Lin ^e   Xu, Zhen Hua ^d   Ou Yang, Dong Sheng ^e   Wang, Yong Jin ^b   Zhou, Hong Hao ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CHANGZHI MEDICAL COLLEGE   (China)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MAYO CLINIC   (United States)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C19; DIAZEPAM; NORDAZEPAM;

ADULT; AREA UNDER THE CURVE; ARTICLE; CHINESE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; GENE DOSAGE; GENETIC VARIABILITY; HUMAN; MALE; NORMAL HUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; ZYGOSITY;

EID: 0033375477     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0009-9236(99)90075-9     Document Type: Article

References (31)

1. 1. Küpfer A, Preisig R. Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man. Eur J Clin Pharmacol 1984;26:753-9.
2. 2. Wilkinson GR, Guengerich FP, Branch RA. Genetic polymorphism of S-mephenytoin hydroxylation. Pharmacol Ther 1989;43:53-76.
3. 3. Wrighton SA, Stevens JC, Becker GW, VanderBranden M. Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4′-hydroxylation. Arch Biochem Biophys 1993;306:240-5.
4. 4. Goldstein JA, Faletto MB, Romkes-Sparks M, Sullivan T, Kitareewwan S, Raucy JL, et al. Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry 1994;33:1743-52.
5. 5. Alván G, Bechtel P, Iselius L, Gundert-Remy U. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol 1990;39: 533-7.
6. 6. Bertilsson L. Geographic/interracial differences in polymorphic drug oxidation: current state of knowledge of cytochrome P450 (CYP) 2D6 and 2C19. Clin Pharmacokinet 1995;29:192-209.
7. 7. Xie HG, Xu ZH, Luo X, Huang SL, Zeng FD, Zhou HH. Genetic polymorphisms of debrisoquine and S-mephenytoin oxidation metabolism in Chinese populations: a meta-analysis. Pharmacogenetics 1996;6:235-8.
8. 8. de Morais SMF, Goldstein JA, Xie HG, Huang SL, Lu YQ, Xia H, et al. Genetic analysis of the S-mephenytoin polymorphism in a Chinese population. Clin Pharmacol Ther 1995;58:404-11.
9. 9. Xiao ZS, Goldstein JA, Xie HG, Blaisdell J, Wang W, Jiang CH, et al. Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele. J Pharmacol Exp Ther 1997;281:604-9.
10. 10. Bertilsson L, Henthorn TK, Sanz E, Tybring G, Säwe EJ, Villén T. Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquine, hydroxylation phenotype. Clin Pharmacol Ther 1989;45:348-55.
11. 11. Zhang Y, Reviriego J, Lou YQ, Sjöqvist F, Bertilsson L. Diazepam metabolism in native Chinese poor and extensive hydroxylators of S-mephenytoin: interethnic differences in comparison with white subjects. Clin Pharmacol Ther 1990;48:496-502.
12. 12. Sohn DR, Kusaka M, Ishizaki T, Shin SG, Jang IJ, Shin JG, et al. Incidence of S-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics. Clin Pharmacol Ther 1992;52:160-9.
13. 13. Wan J, Xia H, He N, Lu YQ, Zhou HH. The elimination of diazepam in Chinese subjects is dependent on the mephenytoin oxidation phenotype. Br J Clin Pharmacol 1996;42:471-4.
14. 14. Bertilsson L, Kalow W. Why are diazepam metabolism and polymorphic S-mephenytoin hydroxylation associated with each other in white and Korean populations but not in Chinese populations? [letter]. Clin Pharmacol Ther 1993;53:608-10.
15. 15. Andersson T, Regárdh CG, Dahl-Paustinen ML, Bertilsson L. Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators. Ther Drug Monit 1990;12:415-6.
16. 16. Chang M, Dahl ML, Tybring G, Gotharson E, Bertilsson L. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics 1995;5:358-63.
17. 17. Küpfer A, Branch RA. Stereoselective mephobarbital hydroxylation cosegregates with mephenytoin hydroxylation. Clin Pharmacol Ther 1985;38:414-8.
18. 18. Adedoyin A, Prakash C, O'Shea D, Blair IA, Wilkinson GR. Stereoselective disposition of hexobarbital and its metabolites: relationship to the S-mephenytoin polymorphism in Caucasian and Chinese subjects. Pharmacogenetics 1994;4:27-38.
19. 19. Birkett DJ, Rees D, Andersson T, Gonzalez FJ, Miners JO, Veronese ME. In vitro proguanil activation to cycloguanil by human liver microsomes is mediated by CYP3A4 isoforms as well as by S-mephenytoin hydroxylase. Br J Clin Pharmacol 1994;37:413-20.
20. 20. Funck-Brentano C, Becquemont L, Leneveu A, Roux A, Jaillon P, Beaune P. Inhibition by omeprazole of proguanil metabolism: mechanism of the interaction in vitro and prediction of in vivo results from the in vitro experiments. J Pharmacol Exp Ther 1997;280:730-8.
21. 21. Xie HG. Direct evidence for the higher frequency of CYP2C19 allelic heterozygotes in Chinese subjects than in white subjects [letter]. Clin Pharmacol Ther 1997;62:691-2.
22. 22. de Morais SMF, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994;269:15419-22.
23. m2 in exon 4, in Japanese subjects. Clin Pharmacol Ther 1996;59:647-53.
24. 24. Edeki TI, Goldstein JA, de Morais SMF, Hajiloo L, Bulter M, Chapdelaine P, et al. Genetic polymorphism of S-mephenytoin 4′-hydroxylation in African-Americans. Pharmacogenetics 1996;6:357-60.
25. 25. Hoskins JM, Shenfield GM, Gross AS. Relationship between proguanil metabolic ratio and CYP2C19 genotype in a Caucasian population. Br J Clin Pharmacol 1998;46:499-504.
26. 26. Katsuki H, Nakamura C, Arimori K, Fujiyama S, Nakano M. Genetic polymorphism of CYP2C19 and lansoprazole pharmacokinetics in Japanese subjects. Eur J Clin Pharmacol 1997;52:391-6.
27. 27. Jack ML, Colburn WA. Pharmacokinetic model for diazepam and its major metabolite desmethyldiazepam following diazepam administration. J Pharm Sci 1983;72: 1318-23.
28. 28. Yasumori T, Li QH, Yamazoe Y, Ueda M, Tsuzaki T, Kato R. Lack of low Km diazepam N-demethylase in livers of poor metabolizers for S-mephenytoin 4′-hydroxylation. Pharmacogenetics 1994;4:323-31.
29. 29. Jung F, Richardson TH, Raucy JL, Johnson EF. Diazepam metabolism by cDNA-expressed hyman 2C P450s: indentification of P4502C18 and P4502C19 as low Km diazepam N-demethylase. Drug Metab Dispos 1997;25: 133-9.
30. 30. Greenblatt DJ, Harmatz JS, Shader RI. Factors influencing diazepam pharmacokinetics: age, sex and liver disease. Int J Clin Pharmacol Biopharm 1978;16:177-9.
31. 31. Xie HG, Huang SL, Xu ZH, Xiao ZS, He N, Zhou HH. Evidence for the effect of gender on activity of (S)-mephenytoin 4′-hydroxylase (CYP2C19) in a Chinese population. Pharmacogenetics 1997;7:115-9